ESMO 2024: Treatment of uHCC - Episode 2

Treatment Decisions Based on BLCL Stage

October 7, 2024

Richard Finn, MD, Olatunji Alese, MD, Daneng Li, MD, Anthony El-Khoueiry, MD, Masatoshi Kudo, MD, PhD, Steven Chan, MD

Panelists discuss current treatment options for unresectable hepatocellular carcinoma, including atezolizumab plus bevacizumab, durvalumab plus tremelimumab, and transarterial chemoembolization, along with the factors influencing treatment decisions.

EP. 1: Current Treatment Landscape – difference between unresectable (uHCC) and metastatic (mHCC)

Now Viewing

EP. 2: Treatment Decisions Based on BLCL Stage

EP. 3: Current Treatment in First Line – IO + TKI or IO + IO

EP. 4: Use of monotherapy (IO or TKI) or localized treatment in First Line

EP. 5: EMERALD-1 Study Results

EP. 6: Discussion and Summary

EP. 7: LEAP-012 Study Results

EP. 8: Discussion of LEAP-012 and EMERALD-1 Study Results and Appropriate Sequencing

EP. 9: ImBRAVE 050 Study Results and Discussion Around Who is a High-Risk Patient

EP. 10: Choosing Second-Line Therapies: Considering First Line Therapy Received

EP. 11: Discussion of CELESTIAL Trial and Second-Line Treatment in Japan

EP. 12: CELESTIAL Sub-Group Discussion

EP. 13: Discussion of RESORCE Trial

EP. 14: Real-World Treatment Data from the Phase 4 STELLAR Trial

EP. 15: Importance of Real-World Data in Supporting Treatment Options

EP. 16: CheckMate 9DW Study Results and Use of Ipiimumab/Nivolumab in First- and Second-Line Treatment

EP. 17: Future Directions for Treating uHCC: Triplet Therapy, Epigenetic Therapy, Cytotoxic Agents, and Antibody-Drug Conjugates (ADCs

Video content above is prompted by the following:

What are the current treatment options, and what factors drive your treatment decision?
- Atezolizumab plus bevacizumab (ImBRAVE 150 – Kudo et al. Liver Cancer. 2022)
- Durvalumab plus tremelimumab (HIMALAYA – Sangro et al. Ann Oncol. 2024)